Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
NCT04989517 is registered in ClinicalTrials.gov with Azora Therapeutics Australia Pty Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
- Lead sponsor
- Azora Therapeutics Australia Pty Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 23, 2021
- Completion date
- March 15, 2023
- Enrollment
- 49 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.